Compare ONCY & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONCY | CPIX |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.1M | 98.3M |
| IPO Year | 2002 | 2007 |
| Metric | ONCY | CPIX |
|---|---|---|
| Price | $0.60 | $7.09 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.14 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 36.8K |
| Earning Date | 11-11-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,010,949.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.75 |
| 52 Week Low | $0.63 | $1.85 |
| 52 Week High | $1.39 | $9.28 |
| Indicator | ONCY | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 24.20 | 46.05 |
| Support Level | N/A | $5.55 |
| Resistance Level | $0.89 | $7.36 |
| Average True Range (ATR) | 0.04 | 0.50 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 8.31 | 34.95 |
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.